Lipocine Inc — Quarterly Cash Flow (NASDAQ:LPCN) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 22.51 M20.5 M18.58 M16.07 M17.01 M Total liabilities 1.51 M1.3 M1.45 M1.93 M2.53 M Total equity 21 M19.2 M17.13 M14.14 M14.48 M Total liabilities & shareholders' equities 22.51 M20.5 M18.58 M16.07 M17.01 M Total debt ————— Net debt —————

Haberler

John W. Higuchi, Lipocine hisselerini 81.199 dolara aldı

Higuchi John W., Lipocine (LPCN) hisselerinden 252.149 dolar aldı

Lipocine CEO’su Patel, 50.749 dolarlık LPCN hissesi aldı

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.13%

Faz 3 denemesi başarısız olunca Lipocine hissesi çakıldı

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates

Lipocine, PPD tedavisi için faz 3 çalışmasında hasta ziyaretlerini tamamladı

Lipocine completes patient visits in phase 3 trial for PPD treatment

H.C. Wainwright, PPD denemesindeki ilerleme üzerine Lipocine hisse fiyat hedefini 15 dolara yükseltti

H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress

Lipocine completes enrollment in phase 3 trial for PPD treatment